30/06/2015 01:17:59 Free Membership Login

Astrazeneca Company Financial Information

 Company name: Astrazeneca
 Company Description: A group engaged in R&D; manufacture & marketing of prescription pharmaceuticals & biological products for healthcare areas such as cardiovascular; neuroscience; oncology; respiratory & inflammation
 EPIC: AZN Trading Currency: GBX
 Market Sector: FE00 ISIN: GB0009895292
 Market Segment: SET0 Share Type: DE
 WWW Address: http://www.astrazeneca.com/ Description: ORD SHS $0.25
 Industry Sector: PHARMACEUTICALS & BIOTECHNOLOGY
 Price Price Change [%] Bid Ask Open High Low Volume
 4,096.50 mages.advfn.com/imagesnew/2/us/down -97.0 [-2.31] 4,102.00 4,103.00 4,054.00 4,150.50 4,051.00 3,232,021
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 51,747.75 1,263.22 0.56 62.30 179.74 65.75 4.39 4,906.00 - 4,051.00

Astrazeneca Key Figures

(at previous day's close)
Market Cap.51,747.75m
Shares In Issue1,263.22m
Prev. Close4,193.50
PE Ratio65.75 
Dividend Yield4.39%
EPS - basic62.30p
Dividend PS179.74p
Dividend Cover- 
Cash Flow PS358.67p
Return On Equity (ROE)6.28%
Operating Margin4.77%
PEG Factor-1.27 
EPS Growth Rate-51.96%
Dividends PS Growth Rate-%
Net Debt20,920.16m
Gross Gearing66.47%
Quick Assets10,432.80m
Net Working Capital566.19m
Intangibles / Fixed Assets80.56%
Turnover PS1,326.09p
Pre-Tax Profit PS63.32p
Retained Profit PS-116.27p
Cash PS323.20p
Net Cash PS-557.47p
Net Tangible Asset Value PS *-655.75p
Net Asset Value PS998.37p
Spread1.00 (0.02%) 

Astrazeneca Balance Sheet

LSE:AZN:Liabilities+EQLSE:AZN:Assets

Share Price Performance

Sample Period HighLow
1 week4,286.004,051.00
4 weeks4,518.504,051.00
12 weeks4,906.004,051.00
1 year4,906.004,051.00

Share Price Chart (5 years)

Astrazeneca Historic Returns

Giorni da oggi OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week4,234.50-138.00-3.264,228.402.594,225.22
4 weeks4,503.50-407.00-9.044,258.132.844,256.89
12 weeks4,655.00-558.50-12.004,465.112.794,463.47
26 weeks4,549.00-452.50-9.954,534.442.724,534.57
1 year4,365.00-268.50-6.154,494.172.604,491.72
3 years2,818.501,278.0045.343,744.842.533,825.91
5 years3,081.001,015.5032.963,442.382.693,455.18

Astrazeneca Key Management Ratios

Astrazeneca Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio38.20 
PE Ratio65.75 
Tobin's Q Ratio 0.90 
Tobin's Q Ratio (excl. intangibles)1.85 
Dividend Yield4.39%
Market-to-Book Ratio4.11 
Price-to-Pre-Tax Profit PS64.70 
Price-to-Retained Profit PS-35.23 
Price-to-Cash Flow PS11.42 
Price-to-Sales PS3.09 
Price-to-Net Tangible Asset Value PS-6.26 
Price-to-Cash PS12.67 
Net Working Capital PS44.82 
Price Pct to Working Capital PS91.40%
Earnings Yield1.52%
Average PE15.84 
Years in average5 
PE to PE average415.15%

Astrazeneca Financial Ratios

(Leverage Ratios)
Debt Ratio52.39%
Debt-to-Equity Ratio1.10 
Debt-to-Equity Ratio (excl. Intgbl)-1.68 
Debt-to-Equity Market Value0.27 
Net Gearing55.62%
Net Gearing (excl. Intangibles)125.03%
Gross Gearing66.47%
Gross Gearing (excl. Intangibles)149.44%
Gearing Under 1 Year29.58%
Gearing Under 1 Year (excl. Intgbl)66.49%
Assets/Equity2.98 
Cash/Equity32.37 
(Liquidity Ratios)
Net Working Capital to Total Assets1.51%
Current Ratio1.05 
Quick Ratio (Acid Test)0.94 
Liquidity Ratio0.37 
Cash & Equiv/Current Assets34.92%
(Solvency Ratios)
Enterprise Value61,555.29m
CFO/Sales0.27 
CFO/Attributable Profit5.72 
CFO/Assets0.12 
CFO/Debt0.18 
Total Debt/Equity Market Value0.48 
Total Debt/Sales1.49 
Total Debt/Pre-Tax Profit31.26 
Total Debt25,002.89m
Total Debt/Net Current Assets44.16%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs6 
Beta (60-Mnth)Beta (36-Mnth)
0.55990.9396
Alpha (60-Mnth)Alpha (36-Mnth)
0.00190.0047

Astrazeneca Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)3.02%
Return On Assets (ROA)1.38%
Net Profit Margin4.73%
Assets Turnover0.29 
Return On Equity (ROE)6.28%
Return On Investment (ROI)1.95%
Dividend Payout Ratio285.71%
Plowback Ratio-185.71%
Growth from Plowback Ratio-6.86%
Net Income Of Revenues-8.77%
(Asset Utilisation Multiples)
Shareholders Equity Turnover0.78 
Fixed Assets Turnover0.45 
Current Assets Turnover0.82 
Net Working Capital Turnover 
Inventory Turnover8.66 
(Other Operating Ratios)
Total Assets-to-Sales3.42 
Debtors-to-Sales63.69%
Debt Collection Period232.46Days

Astrazeneca Dividends

Announcement DateTypeCurr.Dividend AmountPeriod StartPeriod EndEx DateRecord DatePayment DateTotal Dividend Amount
05 Feb 2015FinalUSX190.0012/31/201312/31/201402/19/201502/20/201503/23/2015280.00
31 Jul 2014InterimUSX90.0012/31/201312/31/201408/13/201408/15/201409/15/2014-
06 Feb 2014FinalUSX190.0012/31/201212/31/201302/19/201402/21/201403/24/2014280.00
01 Aug 2013InterimUSX90.0012/31/201212/31/201308/14/201308/16/201309/16/2013-
31 Jan 2013FinalUSX190.0012/31/201112/31/201202/13/201302/15/201303/18/2013280.00
26 Jul 2012InterimUSX90.0012/31/201112/31/201208/08/201208/10/201209/10/2012-
02 Feb 2012FinalUSX195.0012/31/201012/31/201102/15/201202/17/201203/19/2012280.00
28 Jul 2011InterimUSX85.0012/31/201012/31/201108/03/201108/05/201109/12/2011-
27 Jan 2011FinalUSX185.0012/31/200912/31/201002/02/201102/04/201103/14/2011255.00
29 Jul 2010InterimUSX70.0012/31/200912/31/201008/02/201008/04/201009/13/2010-
28 Jan 2010FinalUSX171.0012/31/200812/31/200902/03/201002/05/201003/15/2010230.00
30 Jul 2009InterimUSX59.0012/30/200806/30/200908/05/200908/07/200909/14/2009-
29 Jan 2009FinalUSX150.0012/31/200712/31/200802/04/200902/06/200903/16/2009205.00
31 Jul 2008InterimUSX55.0012/30/200706/30/200808/08/200808/06/200809/15/2008-
31 Jan 2008FinalUSX135.0012/31/200612/31/200702/06/200802/08/200803/17/2008187.00
26 Jul 2007InterimUSX52.0006/30/200606/30/200708/08/200708/10/200709/17/2007-
01 Feb 2007FinalUSX123.0012/31/200512/31/200602/07/200702/09/200703/19/2007172.00
27 Jul 2006InterimUSX49.0012/30/200506/30/200608/09/200608/11/200609/18/2006-
01 Feb 2006FinalUSX92.0012/31/200412/31/200502/08/200602/10/200603/20/2006130.00
29 Jul 2005InterimUSX38.0012/30/200406/30/200508/10/200508/12/200509/19/2005-
27 Jan 2005FinalUSX64.5012/31/200312/31/200402/09/200502/11/200503/21/200594.00
22 Jul 2004InterimUSX29.5012/30/200306/30/200408/11/200408/13/200409/20/2004-
29 Jan 2004FinalUSX54.0012/31/200212/31/200302/18/200402/20/200404/06/200479.50
24 Jul 2003InterimUSX25.5012/30/200206/30/200308/20/200308/22/200310/06/2003-
30 Jan 2003FinalUSX47.0012/31/200112/31/200202/19/200302/21/200304/07/200370.00
25 Jul 2002InterimUSX23.0012/30/200106/30/200208/21/200208/23/200210/07/2002-
31 Jan 2002FinalUSX47.0012/31/200012/31/200102/20/200202/22/200204/08/200270.00
26 Jul 2001InterimUSX23.0012/30/200006/30/200108/22/200108/24/200110/05/2001-
08 Feb 2001FinalUSX47.0012/31/199912/31/200002/21/200102/23/200104/09/200170.00
01 Aug 2000InterimUSX23.0012/30/199906/30/200009/04/200009/08/200010/23/2000-
24 Feb 2000FinalUSX47.0012/31/199812/31/199903/06/200003/10/200004/17/200070.00
03 Aug 1999InterimUSX23.0012/30/199806/30/199909/06/199909/10/199910/25/1999-

Astrazeneca Fundamentals

 31 Dec 2011 (USD)31 Dec 2012 (USD)31 Dec 2013 (USD)31 Dec 2014 (USD)
turnover33,591.00100.00%27,973.00100.00%25,711.00100.00%26,095.00100.00%m
pre tax profit12,367.0036.82%7,718.0027.59%3,267.0012.71%1,246.004.77%m
attributable profit9,983.0029.72%6,297.0022.51%2,556.009.94%1,233.004.73%m
retained profit6,219.0018.51%2,632.009.41%-905.00-3.52%-2,288.00-8.77%m
eps - basic733.00 499.00 204.00 98.00 
eps - diluted730.00 498.00 204.00 98.00 
dividends per share280.00 280.00 280.00 280.00 

Astrazeneca Balance Sheet

 31 Dec 2011 (USD)31 Dec 2012 (USD)31 Dec 2013 (USD)31 Dec 2014 (USD)
LSE:AZN:Liabilities+EQLSE:AZN:AssetsLSE:AZN:Liabilities+EQLSE:AZN:AssetsLSE:AZN:Liabilities+EQLSE:AZN:AssetsLSE:AZN:Liabilities+EQLSE:AZN:Assets
 31 Dec 2011 (USD)31 Dec 2012 (USD)31 Dec 2013 (USD)31 Dec 2014 (USD)
ASSETS
fixed assets fixed assets6,425.0012.16%6,089.0011.37%5,818.0010.41%6,010.0010.26%m
intangibles intangibles20,842.0039.45%26,346.0049.21%26,028.0046.56%32,531.0055.52%m
fixed investments fixed investments4,816.009.12%1,442.002.69%1,482.002.65%1,842.003.14%m
current assets - other current assets - other--%--%--%--%m
stocks stocks1,852.003.51%2,061.003.85%1,909.003.42%1,960.003.34%m
debtors debtors11,324.0021.43%9,895.0018.48%11,445.0020.47%9,892.0016.88%m
cash & securities cash & securities7,571.0014.33%7,701.0014.39%9,217.0016.49%6,360.0010.85%m
TOTAL52,830.00100%53,534.00100%55,899.00100%58,595.00100%m
LIABILITIES
creditors - short creditors - short15,752.0029.82%13,903.0025.97%16,051.0028.71%17,330.0029.58%m
creditors - long creditors - long13,606.0025.75%15,679.0029.29%16,595.0029.69%21,619.0036.90%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
TOTAL29,358.0055.57%29,582.0055.26%32,646.0058.40%38,949.0066.47%m
EQUITY
ord cap, reserves ord cap, reserves23,246.0044.00%23,737.0044.34%23,224.0041.55%19,627.0033.50%m
prefs, minorities prefs, minorities226.000.43%215.000.40%29.000.05%19.000.03%m
TOTAL23,472.0044.43%23,952.0044.74%23,253.0041.60%19,646.0033.53%m
OTHER
NAV Basic- - - - 
NAV Diluted- - - - 

Astrazeneca Cash Flow Statement

31 Dec 2011 (USD)31 Dec 2012 (USD)31 Dec 2013 (USD)31 Dec 2014 (USD)
Operating CF7,821.006,948.007,400.007,058.00m
Pre-Financing CF5,799.005,089.004,511.0026.00m
Retained CF-3,522.00166.001,464.00-2,679.00m

Astrazeneca Brokers

NameActivityTypeMnemonicCode
Evolution Securities LimitedMarket Maker(MME)Broker/DealerEVOEVBGGB21MMT
Nyenburgh Holding B.V.Market Maker(MME)Broker/DealerNYBBNYENNL2B
Winterflood Securities LtdMarket Maker(MME)Broker/DealerWINSWNTSGB2LBIC



Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us lse azn150630 01:17